Like the three other immune checkpoint proteins (PD-1, PD-L1, and CTLA-4), TIGIT expression was also associated with markers of tumor inflammation, including the count of cancer cells within 80 μm of lymphocytes (pan-cancer and BRCA), the total number of lymphocytes in CT + CAS (pan-cancer and BRCA), and the proportional count of lymphocytes to cancer cells within 80 μm of the CSI (LUAD) (Fig. 6bv and Supplementary Fig. 11v). The gene discussed is CTLA4; the disease is neoplasm.